Technology
Health
Biotechnology
aTyr Pharma
$0.609876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$0.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.0531 (-9.51%) Today
+$0.095 (18.81%) After Hours
Why Robinhood?
You can buy or sell aTyr Pharma and other stocks, options, ETFs, and crypto commission-free!
About
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of innovative therapeutic products based on Physiocrine biology. Read More The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler in 2005 and is headquartered in San Diego, CA.
Employees
65
Headquarters
San Diego, California
Founded
2005
Market Cap
16.67M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
523.23K
High Today
$0.5935
Low Today
$0.5048
Open Price
$0.555
Volume
747.63K
52 Week High
$3.05
52 Week Low
$0.3751
Collections
Technology
Health
Biotechnology
Therapy
2015 IPO
US
North America
News
MarketBeatMar 14
Stock Price, News, & Analysis for aTyr Pharma
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enha...
Price Paid on Robinhood
24% Lower
Right Now
52 Week Low
$0.3751
Average Price Paid
$0.7869
52 Week High
$3.05
Earnings
-$0.24
-$0.23
-$0.22
-$0.21
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.22 per share
Actual
-$0.21 per share